Management of heparin-induced thrombocytopenia: A critical comparison of lepirudin and argatroban

Thrombosis Research

Volumn 110, Issue 2-3, 2003, Pages 73-82

  Warkentin, Theodore E ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

Author keywords

Anticoagulation; Argatroban; Direct thrombin inhibitor; Heparin induced thrombocytopenia; Lepirudin; Thrombosis; Warfarin induced necrosis

Indexed keywords

ARGATROBAN; COUMARIN; DANAPAROID; FIBRIN; HEPARIN; LEPIRUDIN; THROMBIN INHIBITOR; WARFARIN;

BLEEDING; CARDIOVASCULAR RISK; CATALYSIS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; GANGRENE; HUMAN; LIMB DISEASE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 0142258733     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(03)00336-0     Document Type: Review

References (38)

1. Warkentin T.E. Heparin-induced thrombocytopenia: pathogenesis and management. Br. J. Haematol. 121:2003;535-555.
2. Smythe M.A., Warkentin T.E., Stephens J.L., Zakalik D., Mattson J.C. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am. J. Hematol. 71:2002;50-52.
3. Warkentin T.E., Roberts R.S., Hirsh J., Kelton J.G. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch. Intern. Med. 2003;. [in press].
4. Warkentin T.E., Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med. 344:2001;1286-1292.
5. Warkentin T.E. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch. Pathol. Lab. Med. 126:2002;1415-1423.
6. Warkentin T.E., Levine M.N., Hirsh J., Horsewood P., Roberts R.S., Gent M.et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332:1995;1330-1335.
7. Warkentin T.E. Clinical picture of heparin-induced thrombocytopenia. Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia. 2nd ed. 2001;43-86 Marcel Dekker, New York.
8. Hong A.P., Cook D.J., Sigouin C.S., Warkentin T.E. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood. 101:2003;3049-3051.
9. Girolami B., Prandoni P., Stefani P.M., Tanduo C., Sabbion P., Eichler P.et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 101:2003;2955-2959.
10. Warkentin T.E., Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am. J. Med. 101:1996;502-507.
11. Wallis D.E., Workman D.L., Lewis B.E., Steen L., Pifarre R., Moran J.F. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am. J. Med. 106:1999;629-635.
12. Lewis B.E., Wallis D.E., Berkowitz S.D., Matthai W.H., Fareed J., Walenga J.M.et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 103:2001;1838-1843.
13. Lewis B.E., Wallis D.E., Leya F., Hursting M.J., Kelton J.G. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch. Intern. Med. 2003;. [in press].
14. Tardy B., Tardy-Poncet B., Fournel P., Venet C., Jospe R., Dacosta A. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. [letter] Thromb. Haemost. 82:1999;1199-1200.
15. Greinacher A., Eichler P., Lubenow N., Kwasny H., Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 96:2000;846-851.
16. Eichler P., Lubenow N., Greinacher A. Results of the third prospective study of treatment with lepirudin in patients with heparin-induced thrombocytopenia (HAT). [abstract] Blood. 100(Suppl. 1):2002;704a.
17. Lubenow N., Eichler P., Leitz T., Greinacher A. Meta-analysis of three prospective studies of lepirudin in the prevention of thrombosis in patients with heparin-induced thrombocytopenia. [abstract] Blood. 100(Suppl. 1):2002;501a-502a.
18. Lubenow N., Eichler P., Greinacher A. Results of a large drug monitoring program confirms the safety and efficacy of Refludan (lepirudin) in patients with immune-mediated heparin-induced thrombocytopenia. [abstract] Blood. 100(Suppl. 1):2002;502a.
19. Greinacher A., Völpel H., Janssens U., Hach-Wunderle V., Kemkes-Matthes B., Eichler P.et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study. Circulation. 99:1999;73-80.
20. Greinacher A., Janssens U., Berg G., Bock M., Kwasny H., Kemkes-Matthes B.et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation. 100:1999;587-593.
21. Farner B., Eichler P., Kroll H., Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb. Haemost. 85:2001;950-957.
22. Chong B.H., Gallus A.S., Cade J.F., Magnani H., Manoharan A., Oldmeadow M.et al. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis. A clinical outcome study. Thromb. Haemost. 86:2001;1170-1175.
23. Lewis B.E., Hursting M.J. Argatroban therapy in heparin-induced thrombocytopenia. Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia. 2nd ed. 2001;381-407 Marcel Dekker, New York.
24. Greinacher A. Recombinant hirudin for the treatment of heparin-induced thrombocytopenia. Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia. 2nd ed. 2001;349-380 Marcel Dekker, New York.
25. Berry C.N., Girardot C., Lecoffre C., Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb. Haemost. 72:1994;381-386.
26. Sheth S.B., DiCicco R.A., Hursting M.J., Montague T., Jorkasky D.K. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb. Haemost. 85:2001;435-440.
27. Hiatt B.K., Macfarlane D.E., Hursting M.J. Transition from argatroban to warfarin in patients with heparin-induced thrombocytopenia. [abstract] Blood. 98:2001;91b.
28. Eichler P., Friesen H.J., Lubenow N., Jaeger B., Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood. 96:2000;2373-2378.
29. Walenga J.M., Ahmad S., Hoppensteadt D., Iqbal O., Hursting M.J., Lewis B.E. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb. Res. 105:2002;401-405.
30. Greinacher A., Lubenow N., Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia abstract. J. Thromb. Hemost. 1(Suppl. 1):2003;OC022.
31. Warkentin T.E., Elavathil L.J., Hayward C.P.M., Johnston M.A., Russett J.I., Kelton J.G. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Intern. Med. 127:1997;804-812.
32. Warkentin T.E., Sikov W.M., Lillicrap D.P. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Am. J. Hematol. 62:1999;44-48.
33. Warkentin TE, Whitlock RP, Teoh KHT. Warfarin-induced multiple digital necrosis associated with heparin-induced thrombocytopenia and Raynaud's phenomenon following aortic valve replacement for adenocarcinoma-associated thrombotic endocarditis. Submitted for publication.
34. Srinivasan A.F., Rice L., Bartholomew J.R., Rangaswamy C., La Perna L., Thompson J.E.et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch. Intern. Med. 2003;. [in press].
35. Warkentin T.E. Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis. Ann. Intern. Med. 135:2001;589-593.
36. Sackett D.L., Haynes R.B., Guyatt G.H., Tugwell P. Deciding whether your treatment has done harm. (chapter 9) Clinical epidemiology. A basic science for clinical medicine. 2nd ed. 1991;283-302 Little, Brown and Company, Boston.
37. Wallis D.E., Quintos R., Wehrmacher W., Messmore H. Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia. Chest. 116:1999;1333-1338.
38. Hirsh J, Warkentin TE, Raschke R, Greinacher A. Heparin. Submitted for publication.